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Hepatitis A virus (HAV) causes acute hepatitis and sometimes leads to fulminant hepatitis. Amantadine is a tricyclic
symmetric amine that inhibits the replication of many DNA and RNA viruses. Amantadine was reported to suppress
HAV replication, and the efficacy of amantadine was exhibited in its inhibition of the internal ribosomal entry site
(IRES) activities of HAV. Interferon (IFN) also has an antiviral effect through the induction of IFN stimulated genes
(ISG) and the degradation of viral RNA. To explore the mechanism of the suppression of HAV replication, we exam-
ined the effects of the combination of amantadine and IFN-alpha on HAV IRES-mediated translation, HAV replicon
replication in human hepatoma cell lines, and HAV KRM003 genotype IIIB strain replication in African green mon-
key kidney cell GL37. IFN-alpha seems to have no additive effect on HAV IRES-mediated translation inhibition by
amantadine. However, suppressions of HAV replicon and HAV replication were stronger with the combination than
with amantadine alone. In conclusion, amantadine, in combination of IFN-alpha, might have a beneficial effect in
some patients with acute hepatitis A.
Short report
Hepatitis A virus (HAV), a member of the family Picor-
naviridae, causes acute hepatitis and occasionally fulmi-
nant hepatitis, a life-threatening disease. As the broad
epidemiological picture of hepatitis A changes, the pub-
lic health importance of this disease is being increasingly
recognized [1]. It is a significant cause of morbidity
worldwide, although the mortality rate due to hepatitis
A is low (improved intensive care and transplantation
have contributed to a reduction in deaths). Improved
sanitation and living standards mean that fewer coun-
tries remain highly endemic, but the risk of HAV infec-
tion is present in countries lacking HAV immunity or
where the endemicity of hepatitis A is low or intermedi-
ate [1]. In such situations, these outbreaks can prove to
be long and difficult to control. Vaccination and inform-
ing the general public about good hygienic measures are
important for the prevention of HAV infection, but new
therapeutic options are also desirable.
Amantadine, a tricyclic symmetric amine, inhibits
HAV replication in vitro [2]. We previously reported
that amantadine inhibits hepatitis A virus internal ribo-
somal entry site (IRES)-mediated translation in human
hepatoma cells [2]. Interferons (IFNs) also exhibit anti-
viral effects against HAV infection [2,3]. In the present
study, we examined the effects of amantadine with or
without IFN-alpha, on HAV IRES activities, HAV subge-
nomic replicon replication and HAV replication in vitro
as a proof of concept for the development of a more
effective treatment to control HAV infection.
First, we evaluated the cytotoxicity of amantadine and
IFN-alpha by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner
salt (MTS) assay. Amantadine concentrations in a range
o f1-1 2 5μg/mL and those of 1 - 150 μg/mL for 12-h
incubation were non-toxic for Huh7 cells and for
HuhT7 cells, respectively (Figures 1A and 1B). Amanta-
dine could be incubated for a short time, e.g., 12 h, with
the cells, and then the dose of amantadine could be
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any medium, provided the original work is properly cited.Figure 1 Effects of amantadine on cell growth and viability. MTS assays of cells 12 h after treatment with amantadine with or without
100 U/mL interferon (IFN)-alpha. (A) Huh7 cells. (B) HuhT7 cells. Data are expressed as mean ± SD.
Figure 2 Structures of reporter constructs used in this study. (A) Structure of HAV genome. (B) Structure of the replication-competent HAV
replicon (HAV replicon) pT7-18f-LUC, which contains an open-reading frame of firefly luciferase (Fluc) flanked by the first four amino acids of
HAV polyprotein and by 12 C-terminal amino acids of VP1. This segment is followed by P2 and P3 domains of HAV polyprotein (HAV strain
HM175 18f) [9,10]. (C) Structure of replication-incompetent HAV replicon (mut) (mut-HAV replicon) pT7-18f-LUCmut, which contains a frame-shift
mutation in the polymerase 3 D [9,10]. (D) Bicistronic reporter constructs: pSV40-HAV IRES was described previously [2,4]. It encodes the Renilla
luciferase genes (Rluc), the internal ribosomal entry site (IRES) HAV HM175, and the firefly luciferase gene (Fluc) under the control of the simian
virus 40 promoter (SV40).
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tion of amantadine and 100 IU/mL IFN-alpha, we did
not observe increased cytotoxicity compared with aman-
tadine alone.
We previously reported that the introduction of
siRNA targeted against the 5’NTR region of HAV
HM175 inhibits HAV IRES-mediated translation and
HAV replication [4]. Interestingly, amantadine and IFN
also inhibited HAV IRES-mediated translation and HAV
replication [2,3,5-8]. Accordingly, we planned to identify
more effective strategies for suppressing HAV IRES-
mediated translation and HAV replication. IRES is an
attractive target for antivirals because HAV IRES is
located in the 5’NTR region, the most conserved region
among HAV strains. In the present study, we evaluated
the HAV antiviral activity of amantadine and IFN-alpha.
We initially examined the effects of this combination on
HAV IRES-mediated translation using a luciferase repor-
ter assay. Huh7 cells were transfected with pSV40-HAV
IRES reporter vector, encoding SV40 promoter driven-
Renilla reniformis and firefly luciferase, separated by
HAV-IRES (Figure 2) [2], and treated with amantadine
and/or IFN-alpha. Inhibition of luciferase activity at
different levels was observed with amantadine with or
without 100 IU/mL IFN-alpha (Figure 3A). Although
the strongest suppression was noted with the combina-
tion of 10 μg/mL amantadine and 100 IU/mL
IFN-alpha, IFN-alpha showed no additive effect on the
translation inhibition by 50-100 μg/mL amantadine.
This finding prompted us to examine whether IFN-
alpha has additive suppression of HAV replicon replica-
tion by amantadine. We have reported that RNA repli-
cation of HAV can be analyzed in a DNA-based
replicon system using HuhT7 cells that stably express
T7-RNA polymerase in the cytoplasm (Figure 1) [9-11].
The luciferase activities determined after transfection of
replicon DNA are a direct measure of RNA translation
and replication. This is because replication in positive-
stranded RNA viruses can be easily assessed with a
viral replicon carrying the luciferase gene in place of
viral structural genes. Moreover, luciferase activity due
to translation or translation and replication can be eval-
uated when the transfection of a replication-competent
replicon (HAV replicon) is compared with that of a
replication-incompetent replicon (mut) (mut-HAV repli-
con) [8].
To further determine the effects of the combination of
amantadine and IFN-alpha on HAV replication, we trans-
fected the HAV replicon or mut-HAV replicon into
HuhT7 cells, and the drugs were added 24 h later. Repor-
ter assays were performed 48 or 72 h after transfection.
The transfection efficacy of HAV replicon was estimated
as 20-30% in our systems. Luciferase activity was normal-
ized with respect to the protein concentration of cell
Figure 3 (A) Effects of amantadine with or without interferon
on the hepatitis A virus (HAV) internal ribosomal entry site
(IRES) activities in Huh7 cells. Approximately 2 × 10
5 cells were
seeded on a 6-well tissue culture plate (Iwaki Glass, Tokyo, Japan) 24
h prior to transfection. pSV40-HAV-IRES (0.3 μg) was transfected into
Huh7 cells using the Effectene transfection reagent (Qiagen, Tokyo,
Japan). 24 h after transfection, amantadine and/or IFN in various
concentrations was added to cells. 48 h after transfection, cell
extracts were prepared, and luciferase assays were performed using
the Dual Luciferase assay system (Toyo Ink, Tokyo, Japan) according
to the manufacturer’s instructions [2]. For controlling the variations
in transcription, IRES activity was assessed by measuring the ratio of
Renilla and firefly luciferases. All samples were run in triplicate.
Renilla and firefly luciferase activities were measured as relative light
units using a luminescencer (JNRII-AB-2300; ATTO, Tokyo, Japan). (B,
C) Effects of amantadine with or without interferon on the
HAV subgenomic replicon replication in HuhT7 cells. (B) 48 h
after transfection and (C) 72 h after transfection. Black columns,
replication-competent HAV replicon; white columns, replication-
incompetent HAV replicon (mut). Relative luciferase activities
without any treatments were set at 1. Data are expressed as mean
(columns) ± SD (vertical lines). *P < 0.05 and **P < 0.01, compared
with untreated control by Student’s t test. #P < 0.01 and ## P <
0.05, compared with amantadine alone or IFN-alpha alone by
Student’s t test.
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tion, the replication rates of the HAV replicon were
100%, 77%, and 44% compared to those of control when
treated with amantadine alone, IFN alone, and their com-
bination, respectively (Figure 3B). On the other hand,
since the mut-HAV replicon cannot replicate, the lucifer-
ase activity (39%, 37%, and 22% compared to those of
control for the same test conditions, respectively) is due
to translation of the viral RNA and not replication.
Amantadine alone showed 52% at 72 h, higher than 37%
at 48 h, supporting the notion that amantadine might
suppress translation of the viral RNA. Suppression effects
of these treatments were stronger in the mut-HAV repli-
con than in the HAV replicon. These findings support
our observation of the suppression of HAV IRES-
mediated translation by amantadine and IFN-alpha. Sup-
pression effects at 48 h after transfection by the combina-
tion of amantadine and IFN-alpha against HAV
replication were stronger than those by amantadine or
IFN-alpha monotreatment. IFN-alpha was more effective
than amantadine against the HAV replicon (P = 0.0027)
(Figure 3B).
Seventy-two hours after transfection, the replication
rates of the HAV replicon were 65%, 56%, and 23%
compared to those of control when treated with aman-
tadine alone, IFN-alpha alone, and their combination,
respectively (Figure 3C). The replication rates of the
mut-HAV replicon were 52%, 30%, and 4% of those of
control, respectively. IFN-alpha was more effective than
amantadine against the replication of HAV replicon or
mut-HAV replicon (P <0 . 0 0 1o rP < 0.001). Suppres-
sion effects of the combination of amantadine and IFN-
alpha at 72 h post-transfection were stronger than those
of amantadine or IFN-alpha monotreatment. Suppres-
sion effects of these treatments were stronger in the
mut-HAV replicon than in the HAV replicon. Moreover,
it is important to note that the effects of this combina-
tion were observed at earlier time points (Figure 3C).
Next, we performed an infectivity assay using the virus
to investigate the effects of combination of amantadine
and IFN-alpha on tissue culture-adapted HAV strain
KRM003 (genotype IIIB, accession no. L20536) propaga-
tion in African green monkey kidney GL37 cells [12-14].
GL37 cell monolayers in 96-well culture plates were
infected with HAV at a multiplicity of infection (MOI)
of 5 or 50 for 1 h at 37°C in a CO2 incubator. Without
removing the inoculum, drug-containing media were
added to appropriate wells. The final concentrations of
amantadine, IFN-alpha, and their combination were
50 μg/ml, 100 IU/ml and 50 μg/ml of amantadine and
100 IU/ml of IFN-alpha, respectively. After incubation
for 72 h, infected cells were evaluated with ELISA. Sup-
pression of HAV replication by the combination of
amantadine and IFN-alpha was stronger than those of
amantadine alone, IFN-alpha alone, and untreated con-
trol (Figure 4).
IFNs are proteins induced by lymphocytes and other
cells including hepatocytes in response to viruses such
as HAV. In virus-infected cells, dsRNA activates anti-
viral interferon pathways and the production of IFN
type I. The secreted IFN type I induces a positive feed-
back loop that results in the expression of interferon-sti-
mulated genes (ISGs), including RNase L and protein
kinase R (PKR) [15]. Our study supports the fact that
the administration of IFN-alpha suppresses HAV repli-
cation through HAV IRES mediated-translation and
other mechanisms and that, on the other hand, amanta-
dine suppresses HAV replication mainly through HAV
IRES mediated-translation.
There are several reports concerning HAV suppres-
sing intracellular dsRNA-induced retinoic acid-inducible
gene I (RIG-I)-mediated IFN regulatory factor 3 (IRF-3)
activation to block induction of IFN [16,17]. Yang et al.
reported that HAV proteins interact with mitochondrial
antiviral signaling protein, an essential component of
virus-activated signaling pathways that induce protective
IFN responses [18]. However, in this study, the
Figure 4 Effects of amantadine with or without interferon on
HAV KRM003 genotype IIIB strain replication in African green
monkey kidney cell GL37. GL37 cell monolayers in 96-well culture
plates were infected with HAV [at a multiplicity of infection (MOI) of
5 or 40] for 1 h at 37°C in a CO2 incubator. Amantadine and/or IFN
was added to cells. After the incubation for 72 h, infected cells were
evaluated with ELISA. The rate of virus survival was measured using
this equation: Virus survival rate (%) = 100 × Absorbance with drug/
Absorbance without drug.
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HAV replication, although endogenous IFNs produced
by cells also may play an important role in inhibiting
viral replication. Further studies will be needed.
Amantadine inhibits the replication of many DNA and
RNA viruses and is also used as a drug for the treat-
ment of Parkinson’s disease [2]. It is known that the M2
protein of influenza A virus is a target of amantadine
[19]. Furthermore, it has been reported to inhibit HAV
IRES-mediated translation and replication by our group
and other researchers [2,3,5-8].
Therefore, we examined the possibilities of the combi-
nation of amantadine and IFN-alpha against HAV
because these two drugs were previously reported to be
effective against HAV [2,3,5-8]. To our knowledge, this
is the first study demonstrating that a combination of
amantadine and IFN-alpha can suppress HAV replica-
tion more effectively than amantadine or IFN-alpha
alone.
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